Includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate
癌症，放射性缀合物管道和最先进的R&D和制造
设施
澳门葡京网赌游戏 has entered into a definitive agreement to acquire 融合 Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). 此次收购标志着澳门葡京网赌游戏通过更有针对性的治疗取代化疗和放疗等传统治疗方案，实现改变癌症治疗和患者预后的雄心迈出了重要一步.
近年来，RCs已成为一种很有前途的癌症治疗方式. 这些药物通过抗体等分子的精确定位，将放射性同位素直接传递给癌细胞, 多肽或小分子. 与传统放射治疗相比，这种方法有许多潜在的优势，包括将对健康细胞的损害降到最低，并使肿瘤能够通过外部束辐射到达.
This acquisition complements 澳门葡京网赌游戏's leading 肿瘤学 portfolio with the addition of the 融合 管道 of RCs, 包括他们最先进的项目, fpi - 2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). fpi - 2265靶向前列腺特异性膜抗原(PSMA), 一种在mCRPC中高度表达的蛋白质, 目前正在进行II期临床试验.
此次收购带来了新的专业知识和开创性的R&D, manufacturing and supply chain capabilities in actinium-based RCs to 澳门葡京网赌游戏. 它还加强了公司在加拿大的存在和承诺.
Susan Galbraith，肿瘤学研究中心执行副总裁&D, 澳门葡京网赌游戏, said: “Between thirty and fifty per cent of patients with cancer today receive radiotherapy at some point during treatment, and the acquisition of 融合 furthers our ambition to transform this aspect of care with next-generation radioconjugates. 与聚变一起, we have an opportunity to accelerate the 发展 of fpi - 2265 as a potential new treatment for prostate cancer, and to harness their innovative actinium-based platform to develop radioconjugates as foundational regimens.”
约翰强悍, 首席执行官, 融合, said: “This acquisition combines 融合’s expertise and capabilities in radioconjugates, 包括澳门葡京赌博游戏行业领先的放射性药物R&D, 管道, 制造和锕-225供应链, with 澳门葡京网赌游戏’s leadership in small molecules and biologics engineering to develop novel radioconjugates. Expanding on our existing collaboration with 澳门葡京网赌游戏 w在这里 we have advanced FPI-2068, EGFR-cMET靶向放射缀合物进入I期临床试验, 这给了澳门葡京赌博游戏一个独特的机会来加速下一代放射缀合物的开发，以改变患者的治疗效果.”
融合将成为澳门葡京网赌游戏的全资子公司, 在加拿大和美国的业务仍在继续.
金融方面的考虑
根据最终协议的条款, 澳门葡京网赌游戏, 通过子公司, will acquire all of 融合’s outstanding shares pursuant to a plan of arrangement for a price of $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. The upfront cash portion of the consideration represents 交易价值约为2美元bn, 比融合 10美元的收盘价溢价97%.64 on 18th March 2024 and an 85% premium to the 30-day volume-weighted average price (VWAP) of $11.在此公告之前37. 结合, 预付和最大潜在或有价值支付所代表的, 如果实现, 交易价值约为2美元.40亿美元，较18日融合的收盘价溢价126%th 较30天VWAP溢价111%. 作为交易的一部分, 澳门葡京网赌游戏将获得这笔现金, 融合资产负债表上的现金等价物和短期投资, 截至31年，总计2.34亿美元st 2023年12月.
该交易预计将于2024年第二季度完成, 以惯例成交条件为准, 包括融合股东的批准和监管许可.
笔记
肿瘤学中的放射缀合物
RCs结合了抗体的精确靶向, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells. 通过寻找癌细胞, RCs provide a more precise mechanism of cancer cell killing compared with traditional radiation therapy, 目的是提高疗效，同时尽量减少对健康细胞的毒性. RCs通过全身给药进行管理, 这使得它们能够用于外部光束辐射无法到达的肿瘤类型，以及靶向从主要肿瘤扩散到身体其他部位的癌细胞.
fpi - 2265
fpi - 2265 is an actinium-225 based PSMA-targeting RC for mCRPC, currently in a Phase II trial.
Actinium-225 emits alpha particles and holds the promise of being a next-generation radioisotope in cancer treatment. 通过在更短的距离内提供更大的辐射剂量, alpha particles such as actinium-225 have the potential for more potent cancer cell killing, 有针对性的交付, 从而最大限度地减少对周围健康组织的损害.
关于融合
融合 Pharmaceuticals is a clinical-stage 肿瘤学 company focused on developing next-generation RCs. 核聚变将发射α粒子的同位素与各种靶向分子连接起来，选择性地将发射α粒子的有效载荷传递给肿瘤. 融合的临床阶段开发组合包括lead项目, fpi - 2265, 针对mCRPC的PSMA和针对实体肿瘤的新型RCs.
澳门葡京网赌游戏在 肿瘤学
澳门葡京网赌游戏 is leading a revolution in 肿瘤学 with the ambition to provide cures for cancer in every form, 跟随科学去了解癌症及其所有的复杂性, 开发并向患者提供改变生活的药物.
该公司专注于一些最具挑战性的癌症. 正是通过持续的创新，澳门葡京网赌游戏建立了行业中最多样化的产品组合和管道之一, with the potential to catalyse changes in the practice of medicine and transform the patient experience.
澳门葡京网赌游戏的愿景是重新定义癌症治疗和, 有一天,, 消除癌症作为死亡原因.
附加信息和在哪里可以找到它
与拟议的交易有关, 融合 intends to file a proxy circular with the Securities and Exchange Commission (SEC). 澳门葡京赌博游戏敦促投资者和证券持有人在代理通函可用时完整阅读其内容，以及向SEC提交的与拟议交易相关的任何其他文件或通过引用纳入代理通函的文件，因为它们将包含有关拟议交易和相关事项的重要信息.
投资者 and 证券交易委员会urity holders will be able to obtain free copies of the proxy statement and other relevant documents, 当这些文件提交给SEC时, 在美国证券交易委员会的网站www上.证券交易委员会.政府. 澳门葡京网赌游戏向美国证券交易委员会提交的文件副本可在澳门葡京网赌游戏互联网网站的投资者关系页面免费获得，网址为www.澳门葡京网赌游戏.com/investor-relations.html. Copies of the documents filed with the SEC by 融合 may be obtained at no charge under the “投资者 & 融合网站的“媒体”部分 http://ir.fusionpharma.com/sec-filings.
征集活动的参与者
本通讯不构成购买或出售任何证券的要约或征求购买或出售任何证券的要约或征求任何投票或批准. 该通信不能替代融合可能向SEC提交的与拟议交易相关的任何通知.
澳门葡京网赌游戏, 公司董事、某些高级管理人员和其他雇员可以, 根据证券交易委员会的规定, be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. 有关这些人的资料, 包括他们各自直接或间接利益的描述, 通过证券持有或其他方式, 在向美国证券交易委员会提交代理声明时，将包括哪些内容. 有关澳门葡京网赌游戏董事和执行官的信息也可在澳门葡京网赌游戏于20日向美国证券交易委员会提交的表格20- f中获得th February 2024, and other documents subsequently filed by 澳门葡京网赌游戏 with the SEC. These documents will be available free of charge from the sources indicated above.
融合, 公司董事、某些高级管理人员和其他雇员可以, 根据证券交易委员会的规定, be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. 有关这些人的资料, 包括他们各自直接或间接利益的描述, 通过证券持有或其他方式, 在向美国证券交易委员会提交代理声明时，将包括哪些内容. Information about 融合’s directors and executive officers is also available in 融合’s Form 10-K filed with the SEC on 16th 2023年3月, 融合公司的年度股东大会委托书, 是在27日提交给SEC的吗th 以及融合随后向美国证券交易委员会提交的其他文件. These documents will be available free of charge from the sources indicated above.
前瞻性陈述
本文件可能包含非历史事实陈述, 或"前瞻性陈述",，包括澳门葡京网赌游戏对融合的拟议收购. 此类前瞻性陈述包括, 但不限于, the ability of 澳门葡京网赌游戏 and 融合 to complete the transactions contemplated by the arrangement agreement, including the parties’ ability to satisfy the conditions set forth in the arrangement agreement, 有关完成交易的预期时间表的陈述, 澳门葡京网赌游戏和融合的信念和期望以及关于澳门葡京网赌游戏拟议收购融合所寻求的利益的陈述, 此次收购对澳门葡京网赌游戏和融合的潜在影响, 安排协议终止的可能性, 以及FPI 2265的预期收益和成功, 和其他管道产品或任何组合产品. 这些陈述是基于澳门葡京网赌游戏和融合管理层当前的信念和期望，并受到重大风险和不确定性的影响. 不能保证拟议交易的完成条件将在预期的时间表上得到满足，也不能保证fpi - 2265将获得必要的监管批准，或者在批准后证明其商业成功. 如果基本假设被证明是不准确的，或者风险或不确定性成为现实, actual results may differ materially from those set forth in the forward-looking statements.
风险和不确定性包括, 但不限于, uncertainties as to the timing of the proposed transaction; uncertainties as to how many of 融合’s shareholders will vote in favour of the proposed transaction; the possibility that various conditions to the consummation of the proposed transaction may not be satisfied or waived; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the transactions contemplated by the arrangement agreement and the impact of the announcement and pendency of the transactions on 融合’s business; the risk that shareholder litigation in connection with the proposed transaction may result in significant costs of defence, indemnification and liability; the possibility that the achievement of the specified milestone described in the contingent value rights agreement may take longer to achieve than expected or may never be achieved and the resulting contingent milestone payment may never be realised; general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of COVID 19; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; competition from other products; and challenges in在这里nt in new product 发展, 包括获得监管部门的批准.
Neither 澳门葡京网赌游戏 nor 融合 undertakes any obligation to publicly update any forward-looking statement, 是否是新信息的结果, 未来事件或其他, 除非法律规定. 可能导致结果与前瞻性陈述中描述的结果产生重大差异的其他因素可以在截至31年的澳门葡京网赌游戏表格20f年度报告中找到st 以及截至31年12月的融合年度10k表格报告st 2023年12月, in each case as amended by any subsequent filings made with the SEC. These and other filings made by 澳门葡京网赌游戏 and 融合 with the SEC are available at www.证券交易委员会.政府.
澳门葡京网赌游戏(LSE/STO/Nasdaq: AZN)是一家全球性制药公司, 以科学为主导的澳门葡京赌博游戏公司，专注于发现, 发展, 以及肿瘤学处方药的商业化, 罕见疾病, 和澳门葡京赌博游戏, 包括心血管, 肾 & 代谢、呼吸 & 免疫学和疫苗 & 免疫疗法. 总部设在剑桥, UK, 澳门葡京网赌游戏 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 请访问 澳门葡京网赌游戏.com 并在社交媒体上关注公司 @澳门葡京网赌游戏
联系人
艾德里安·坎普
公司秘书
澳门葡京网赌游戏